Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial
To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]
Assessing Lower Limb Strength and Walking Ability in Individuals with Multiple Sclerosis
The research study aims to investigate strength in the lower limb and its association with walking ability. In addition, other factors related to Multiple Sclerosis (MS) that may affect walking, including spasticity, balance, leg sensation and contractures in the ankle, will be assessed. We hope to use the information we get from this research study […]
ACEMS: Aspirin, Cooling and Exercise in Multiple Sclerosis
This study aims to observe the effectiveness of a practical cooling strategy (cold water spray bottle skin cooling) in reducing heat-related fatigue in hot conditions for people with MS. Participants will complete 5 sessions in total: • 3 practice sessions (1.5hr each): two cycling, handgrip & balance sessions in room temperature conditions, and one in […]
Testing a new ice vest that could help people experiencing Multiple Sclerosis exercise
To investigate the acute effect of the UnderCool 2.0 cooling vest during high-intensity exercise in a heat sensitive MS population on; i) body temperatures and sweating, ii) feelings of exertion and hotness, iii) MS symptoms that are aggravated by heat, and iv) Concealability, comfort and functionality. With a controlled, cross-over design, 20 participants diagnosed with […]
SARS-CoV-2 antibody after COVID-19 vaccination in patients with multiple sclerosis
COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to […]
The QUEST initiative: QUality of life Evaluation STudy: Assessing Health Related Quality of Life in patients receiving medicinal cannabis
You are invited to take part in a research study exploring quality of life in patients accessing medicinal cannabis. People accessing medicinal cannabis may have a range of conditions and symptoms that impact their quality of life. We would like to know how these conditions and symptoms impact quality of life and if this changes […]
Crisis resilience in persons with multiple sclerosis (C-RIMS)
Community disasters, such as floods and bushfires, affect many towns and communities. The crisis can last for several months, with effects being felt for much longer. Prior preparation for a crisis can help with feelings of coping and maintaining your health during this time. There are a number of tools available to help you prepare […]
Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis
We propose to study the benefits and risks of Autologous Haematopoetic Stem Cell Transplant (AHSCT) in people who have an aggressive form of MS not controlled by conventional treatment. Participants will have AHSCT at The Alfred hospital, and they will be closely monitored for 5 years post the transplant to ensure their safety, and also […]
A Phase II observational study of Haematopoietic Stem Cell Transplantation for highly active, treatment resistant MS
This trial is testing whether an autologous (self) haematopoietic stem cell transplant (AHSCT) for highly active, treatment resistant multiple sclerosis reduces MS disease activity over 5 years. The treatment involves: treatment, collection and freezing of stem cells from the patient’s blood; chemotherapy (BEAM-ATG) to destroy the immune system; reinfusion of the patient’s own stem cells. […]